PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15694923-0	2005	Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits.	Galantamine	54-65	acetylcholinesterase	Rattus norvegicus	17-37	
15694923-1	2005	Galantamine is a rather weak acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer"s disease, with possible additional allosteric potentiating effects at the nicotinic ACh receptor (nAChR).	Galantamine	0-11	acetylcholinesterase	Rattus norvegicus	29-49	
15694923-1	2005	Galantamine is a rather weak acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer"s disease, with possible additional allosteric potentiating effects at the nicotinic ACh receptor (nAChR).	Galantamine	0-11	acetylcholinesterase	Rattus norvegicus	51-55	
15694923-2	2005	Earlier data from in vitro biochemical tests suggest that donepezil is 40- to 500-fold more potent than galantamine in inhibiting AChE.	Galantamine	104-115	acetylcholinesterase	Rattus norvegicus	130-134	
15694923-3	2005	In this study, both brain levels and Ki values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit after subcutaneous application were determined.	Galantamine	85-96	acetylcholinesterase	Rattus norvegicus	51-55	
15694923-7	2005	Ki values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3 microg/g in rats, 8.3 and 0.65 microg/g for mice, and 19.1 and 1.3 microg/g in rabbits.	Galantamine	39-50	acetylcholinesterase	Rattus norvegicus	19-23	
15694923-8	2005	The data also suggest that for a similar degree of brain AChE inhibition, 3-15 times higher galantamine than donepezil doses are needed.	Galantamine	92-103	acetylcholinesterase	Rattus norvegicus	57-61